FES Therapy + Task-Specific Training for Spinal Cord Injury

N/A

Waitlist Available

Led By Julio Furlan

Research Sponsored by University Health Network, Toronto

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Must not have

Other neurological diseases (i.e. peripheral neuropathies)

Contraindications for neurophysiological tests

Timeline

Screening 3 weeks

Treatment Varies

Follow Up change in baseline ntf-3 at 3 & 6 months

Awards & highlights

No Placebo-Only Group

Summary

This trial will test whether earlier delivery of FEST+TST after SCI leads to better functional and neurological recovery compared to later delivery.

Who is the study for?

This trial is for individuals in the early stages (less than 3 months) after a traumatic spinal cord injury at the neck level that still allows for some movement. It's not suitable for those with other medical conditions affecting treatment, neurological diseases, severe mental illness, learning disabilities, recent substance abuse, MRI contraindications, or sensory deficits impacting tests.

What is being tested?

The study examines if the timing of functional electrical stimulation therapy combined with task-specific training (FEST+TST) affects recovery of function and nerve health following a cervical spinal cord injury.

What are the potential side effects?

While specific side effects are not listed here, FES Therapy can sometimes cause muscle fatigue or skin irritation under electrode sites. Task-specific training may lead to general tiredness or muscle soreness.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have a neurological condition like peripheral neuropathy.

Select...

I cannot undergo certain nerve function tests.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ change in baseline neuromuscular junction transmission at 3 & 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~change in baseline neuromuscular junction transmission at 3 & 6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and change in baseline neuromuscular junction transmission at 3 & 6 months for reporting.